

## Списък с научни публикации

представен от  
маг.фарм. Христо Пламенов Върбанов, Dr.rer.nat.

---

Общ брой публикации в международни реферирани списания с импакт фактор: **27**

- ◇ [ORCID: 0000-0003-4450-7332](https://orcid.org/0000-0003-4450-7332)
- ◇ Публикации, в които кандидатът е първи автор: **9** (публикации номер 2, 6, 7, 14, 16, 17, 18, 20 и 22 от приложения списък)
- ◇ Публикации, в които кандидатът е кореспондиращ автор (\*corresponding author): **6** (публикации номер 1, 2, 6, 7, 8 и 22 от приложения списък)
- ◇ Публикации, във връзка с придобиване на докторска степен: **3** (публикации номер 16, 17 и 18 от приложения списък). Линк към дисертацията: <https://phaidra.univie.ac.at/open/o:1299931>
- ◇ Публикации, представени за конкурса в група от показатели В: 1-8 от приложения списък
- ◇ Публикации, представени за конкурса в група от показатели Г: 9-15, 19-27 от приложения списък

1. Multifunctional Pt(IV) prodrug candidates featuring the carboplatin core and deferoxamine. S. Harringer, M. Hejl, E. A. Enyedy, M. A. Jakupec, M. S. Galanski, B. K. Keppler, P. J. Dyson, **H. P. Varbanov\***; *Dalton Trans.*, **2021**, 50, 8167-8178. IF: 4.39, **Q1**  
<https://doi.org/10.1039/D1DT00214G>.

2. Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis. **H. P. Varbanov\***, F. Kuttler, D. Banfi, G. Turcatti, P. J. Dyson\*; *PLoS ONE*, **2019**, 14(1): e0211268. **Q1**  
<https://doi.org/10.1371/journal.pone.0211268>.

3. Development and validation of liquid chromatography-based methods to assess the lipophilicity of cytotoxic platinum(IV) complexes. M. H. M. Klose, S. Theiner, **H. P. Varbanov**, D. Hoefler, V. Pichler, M. Galanski, S. M. Meier-Menches\*, B. K. Keppler\*; *Inorganics*, **2018**, 6(4), 130. (2018 *Inorganics* Best Paper Award) **Q3**  
<https://doi.org/10.3390/inorganics6040130>.

4. The impact of whole human blood on the kinetic inertness of platinum(IV) prodrugs – an HPLC-ICP-MS study.

S. Theiner, M. Grabarics, L. Galvez, **H. P. Varbanov**, N. S. Sommerfeld, M. Galanski, B. K. Keppler, G. Koellensperger\*; *Dalton Trans.*, **2018**, 47, 5252-5258. **Q1**  
<https://doi.org/10.1039/C7DT04537A>.

5. Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes.

D. Höfer, **H. P. Varbanov**, M. Hejl, M. A. Jakupec, A. Roller, M. Galanski\*, B. K. Keppler\*; *J. Inorg. Biochem.*, **2017**, 174, 119–129. **Q2**  
<https://doi.org/10.1016/j.jinorgbio.2017.06.005>.

6. Oxaliplatin reacts with DMSO only in the presence of water.

**H. P. Varbanov\***, D. Ortiz, D. Höfer, L. Menin, M. Galanski, B. K. Keppler, P. J. Dyson\*; *Dalton Trans.*, **2017**, 46, 8929–8932. (with inner cover picture) **Q1**  
<https://doi.org/10.1039/c7dt01628j>.

7. Repositioning approved drugs for the treatment of problematic cancers using a screening approach.

**H. P. Varbanov\***, F. Kuttler, D. Banfi, G. Turcatti, P. J. Dyson\*; *PLoS ONE*, **2017**, 12(2): e0171052. **Q1**  
<https://doi.org/10.1371/journal.pone.0171052>.

8. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.

S. Goeschl, **H.P. Varbanov\***, S. Theiner, M.A. Jakupec\*, M. Galanski, B.K. Keppler; *J. Inorg. Biochem.*, **2016**, 160, 264-274. **Q2**  
<https://doi.org/10.1016/j.jinorgbio.2016.03.005>.

9. Prediction of logP for Pt(II) and Pt(IV) complexes: Comparison of statistical and quantum-chemistry based approaches.

I.V. Tetko\*, **H.P. Varbanov**, M. Galanski, M. Talmaciu, J.A. Platts, M. Ravera, E. Gabano; *J. Inorg. Biochem.*, **2016**, 156, 1-13. **Q2**  
<https://doi.org/10.1016/j.jinorgbio.2015.12.006>.

10. Multi-scale imaging of anticancer platinum(IV) compounds in murine tumor and kidney.  
A.A. Legin, S. Theiner, A. Schintlmeister, S. Reipert, P. Heffeter, M.A. Jakupec, J. Mayr,  
**H.P. Varbanov**, C.R. Kowol, M. Galanski, W. Berger, M. Wagner, B.K. Keppler\*;  
*Chem. Sci.*, **2016**, 7(5), 3052-3061. **Q1**

<https://doi.org/10.1039/c5sc04383b>.

11. Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy.

D. Hoefler, **H.P. Varbanov**, A. Legin, M.A. Jakupec, A. Roller, M. Galanski\*, B.K. Keppler\*;  
*J. Inorg. Biochem.*, **2015**, 153, 259-271. **Q1**

<https://doi.org/10.1016/j.jinorgbio.2015.08.018>.

12. Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.

S. Theiner, C. Kornauth, **H. P. Varbanov**, M. Galanski, S. Schoonhoven, P. Heffeter, W. Berger, A. E. Egger\*, B. K. Keppler; *Metallomics*, **2015**, 7(8), 1256-1264. **Q1**

<https://doi.org/10.1039/c5mt00028a>.

13. Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.

S. Theiner, **H. P. Varbanov**, M. Galanski, A. E. Egger, W. Berger, P. Heffeter\*, B. K. Keppler\*;  
*J. Biol. Inorg. Chem.*, **2015**, 20(1), 89-99. **Q1**

<https://doi.org/10.1007/s00775-014-1214-6>.

14. A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.

**H. P. Varbanov**, S. Göschl, P. Heffeter, S. Theiner, A. Roller, F. Jensen, M. A. Jakupec, W. Berger, M. Galanski\*, B. K. Keppler\*;  
*J. Med. Chem.*, **2014**, 57(15), 6751-6764. **Q1**

<https://doi.org/10.1021/jm500791c>.

15. Design, synthesis and comparative cytotoxic investigation of platinum(II) complexes with some derivatives of 5-methyl-5-(4-pyridyl)hydantoin.

A. Bakalova\*, R. Buyukliev, **H. Varbanov**, G. Momekov, *Inorg. Chim. Acta*, **2014**, 423, 46-51. **Q2**

<https://doi.org/10.1016/j.ica.2014.07.030>.

16. Theoretical Investigations and Density Functional Theory Based Quantitative Structure–Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes.

**H.P. Varbanov**, M.A. Jakupec, A. Roller, F. Jensen\*, M. Galanski\*, B.K. Keppler; *J. Med. Chem.*, **2013**, 56, 330-344. **Q1**

<https://doi.org/10.1021/jm3016427>.

17. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.

**H.P. Varbanov**, S.M. Valiahdhi, C.R. Kowol, M.A. Jakupec, M. Galanski\*, B.K. Keppler\*; *Dalton Trans.*, **2012**, 41, 14404-14415. (with inner cover picture) **Q1**

<https://doi.org/10.1039/C2DT31366A>.

18. Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine) platinum(IV) complexes with higher cytotoxicity than cisplatin.

**H. Varbanov**, S.M. Valiahdhi, A.A. Legin, M.A. Jakupec, A. Roller, M. Galanski\*, B.K. Keppler\*; *Eur. J. Med. Chem.*, **2011**, 46, 5456-5464. **Q1**

<https://doi.org/10.1016/j.ejmech.2011.09.006>.

19. Platinum Complexes with 5-Methyl-5(4-pyridyl)hydantoin and its 3-Methyl Derivatives: Synthesis and Cytotoxic Activity - Quantitative Structure-Activity Relationships.

A. Bakalova\*, **H. Varbanov**, R. Buyukliev, G. Momekov, D. Ivanov, I. Doytchinova; *Archiv der Pharmazie*, **2011**, 344(4), 209-216. **Q1**

<https://doi.org/10.1002/ardp.201000182>.

20. Synthesis of palladium(II) complexes with 3-amino-5-methyl-5-(4-pyridyl)-hydantoin: cytotoxic and antimicrobial investigations and comparison with their platinum analogues.

**H. Varbanov**, A. Bakalova\*, R. Buyukliev, G. Momekov, R. Baykushev; *Trans. Met. Chem.*, **2010**, 35, 457–461. **Q3**

<https://doi.org/10.1007/s11243-010-9349-y>.

21. Novel Pt(II) and Pt(IV) complexes with 3-amino-5-methyl-5-(4-pyridyl)- 2,4-imidazolinedione. Synthesis, physicochemical, chemometric and pharmacological investigation.

A. Bakalova\*, **H. Varbanov**, R. Buyukliev, S. Stanchev, G. Momekov, D. Ivanov; *Inorg. Chim. Acta*, **2010**, 363, 1568–1576. **Q2** <https://doi.org/10.1016/j.ica.2010.01.008>.

22. 3-Amino-5-methyl-5-(4-pyridyl)hydantoin.

**H. Varbanov\***, R. Buyukliev, A. Bakalova, A. Roller; *Acta Cryst.*, **2009**, E65, o953. IF: 0.41, **Q3**

<https://doi.org/10.1107/S1600536809011404>.

23. In Vitro Biochemical and Pharmacological Evaluation of a Novel Cytotoxic Dinuclear Pt(II) Complex with 3-amino-5-methyl-5-phenylhydantoin: Cytotoxicity, Induction of Apoptosis, DNA-binding and Processing of the DNA Adducts.

G. T. Momekov, I. Ugrinova, E. A. Pasheva, A. G. Bakalova, **H. P. Varbanov**, D. V. Ferdinandov, D. S. Ivanov, S. M. Konstantinov\*; *Annals of the New York Academy of Sciences*, **2009**, 1171, 649–658. **Q1**

<https://doi.org/10.1111/j.1749-6632.2009.04693.x>.

24. DFT study of the structure and spectral behavior of new Pt(II) complexes with 5-methyl-5(4-pyridyl)hydantoin.

A. Bakalova\*, **H. Varbanov**, S. Stanchev, D. Ivanov, F. Jensen; *Int. J. Quant. Chem.*, **2009**, 109, 826-836. **Q2**

<https://doi.org/10.1002/qua.21890>.

25. Palladium(II) complexes with 5-methyl-5-(4-pyridil)-2,4-imidazolidendione. Synthesis, thermogravimetric and cytotoxic investigation.

A. Bakalova\*, **H. Varbanov**, R. Buyukliev, G. Momekov, D. Ivanov; *J. Therm. Anal. and Cal.*, **2009**, 95, 241-246. **Q2**

<https://doi.org/10.1007/s10973-007-8937-3>.

26. Synthesis, characterization and biological activity of Pt(II) and Pt(IV) complexes with 5-methyl-5-(4-pyridyl)-2,4-imidazolidenedione.

A. Bakalova\*, **H. Varbanov**, R. Buyukliev, G. Momekov, D. Ferdinandov, S. Konstantinov and D. Ivanov; *Eur. J. Med. Chem.*, **2008**, 43, 958-965. **Q2**

<https://doi.org/10.1016/j.ejmech.2007.06.025>.

27. Synthesis and crystal structure of new Pt(II) complex with 3-amino-5-methyl-5-phenyl hydantoin.

A. Bakalova\*, R. Petrova, B. Shivatchev, **H. Varbanov**; *J. Coord. Chem.*, **2007**, 60, 15, 1701-1707. **Q2**

<https://doi.org/10.1080/00958970701526226>.

Дата: 01.12.2021

маг.фарм. д-р Христо П. Върбанов